Algen Biotechnologies, a venture-backed platform therapeutics company from the Illumina Accelerator, has created a rapid CRISPR-based screening platform to identify repurposed drugs for COVID-19. This is based on a screening platform for infectious diseases caused by RNA viruses (such as COVID-19). The use case for the technology includes repurposing existing drugs on the market, as well as identifying novel therapeutics.
Please contact Christine Du, the Co-Founder of Algen, if you would like further information: email@example.com
*this post has been passed to the PLG by a member, the PLG has no affiliation to Algen Biotechnologies and does not accept any liability whatsoever from using this information*